A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
The announcement comes a month after Mylan NV said it will recall all lots of its blood pressure medicines containing valsartan, an angiotensin II receptor blocker, after global health authorities clamped down on the drug.
- Wegovy now in Canada: Who should (and shouldn’t) use the weight-loss drug
- A spoonful of olive oil a day could reduce risk of death from dementia: study
- N.B. woman must move to Toronto for life-saving lung transplant. She can’t afford to go
- Amid bird flu spread, Canada boosts surveillance and testing at border
Comments